Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy

Blinatumomab is a CD19/CD3-bispecific T-cell receptor-engaging (BiTE) antibody with efficacy in refractory B-precursor acute lymphoblastic leukemia. Some patients treated with blinatumomab and other T cell-activating therapies develop cytokine release syndrome (CRS). We hypothesized that patients wi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Teachey, David T., Rheingold, Susan R., Maude, Shannon L., Zugmaier, Gerhard, Barrett, David M., Seif, Alix E., Nichols, Kim E., Suppa, Erica K., Kalos, Michael, Berg, Robert A., Fitzgerald, Julie C., Aplenc, Richard, Gore, Lia, Grupp, Stephan A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2013
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4123427/
https://ncbi.nlm.nih.gov/pubmed/23678006
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-02-485623
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados